Wells Fargo downgraded Axonics (AXNX) to Equal Weight from Overweight with a price target of $71, up from $68, after the company entered into a definitive agreement to be acquired by Boston Scientific (BSX) for $71 in cash per share, representing an equity value of approximately $3.7B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXNX:
- Axonics downgraded to Peer Perform from Outperform at Wolfe Research
- Axonics downgraded to Sector Perform from Outperform at RBC Capital
- M & A News: Boston Scientific (NYSE:BSX) to Acquire Axonics in $3.7B Deal
- Axonics to be acquired by Boston Scientific for $71 per share
- Axonics reports preliminary Q4 revenue $109.3M-$109.7M, consensus $105.53M